Pramipexole

How to order Pramipexole

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Pramipexole on Prescriptsy

Pramipexole is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Pramipexole is a non-ergot dopamine agonist used to treat the motor symptoms of Parkinson's disease and moderate-to-severe restless legs syndrome (RLS).

It is available as immediate-release tablets (taken two or three times daily) and prolonged-release tablets (taken once daily). Pramipexole is a prescription-only medicine (POM) in the United Kingdom.

This page provides a detailed clinical guide to pramipexole, including how it works, dosage instructions, side effects, safety warnings, and how to obtain it in the United Kingdom.

Important safety information about pramipexole

Before reading further, please note these essential safety points.

• Pramipexole may cause impulse control disorders, including pathological gambling, compulsive spending, binge eating, and hypersexuality. Patients and carers must monitor for these behaviours.
• Pramipexole may cause sudden-onset sleep without warning. Do not drive or operate machinery if affected. Inform the DVLA.
• Do not stop pramipexole suddenly. Abrupt withdrawal can cause a serious withdrawal syndrome.
• Dose adjustment is required in patients with kidney impairment.
• Report any hallucinations, confusion, or behavioural changes to your prescriber promptly.

Understanding Parkinson's disease

Parkinson's disease is a progressive neurodegenerative condition caused by the loss of dopamine-producing neurons in the substantia nigra, a region of the midbrain.

Dopamine is a neurotransmitter essential for the smooth, coordinated control of movement.

As dopamine levels fall, the characteristic motor symptoms of Parkinson's disease emerge: resting tremor (shaking), rigidity (stiffness), bradykinesia (slowness of movement), and postural instability (impaired balance).

In addition to motor symptoms, Parkinson's disease causes a wide range of non-motor symptoms, including depression, anxiety, sleep disturbance, cognitive impairment, constipation, urinary problems, fatigue, pain, and apathy.

In the UK, approximately 145,000 people live with Parkinson's disease, and around 18,000 new cases are diagnosed each year.

The condition typically develops after the age of 60, though approximately 5% of cases are diagnosed under 50 (young-onset Parkinson's disease).

There is currently no cure for Parkinson's disease; treatment focuses on managing symptoms and maintaining quality of life for as long as possible.

Levodopa remains the most effective symptomatic treatment.

Dopamine agonists such as pramipexole may be used as monotherapy in early Parkinson's disease (particularly in younger patients, to delay the introduction of levodopa and reduce the risk of motor complications) or as adjunctive therapy alongside levodopa in more advanced disease.

Understanding restless legs syndrome

Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is a common neurological condition characterised by an irresistible urge to move the legs, usually accompanied by uncomfortable or unpleasant sensations described as crawling, tingling, aching, or pulling.

Symptoms occur predominantly at rest and in the evening or at night, and are partially or completely relieved by movement.

RLS can significantly disrupt sleep and quality of life.

In the UK, RLS affects approximately 5% to 10% of adults, though many cases are mild and do not require treatment.

Moderate-to-severe RLS that affects sleep and daily function may be treated with dopamine agonists such as pramipexole, though treatment duration should be limited where possible due to the risk of augmentation.

How pramipexole works

Pramipexole directly stimulates dopamine receptors in the brain, bypassing the need for dopamine synthesis.

It has high selectivity for the D2 subfamily of dopamine receptors, with particular affinity for the D3 subtype.

In Parkinson's disease, stimulation of D2 and D3 receptors in the striatum compensates for the dopamine deficiency caused by neuronal loss in the substantia nigra, improving motor function.

The D3 receptor is concentrated in the mesolimbic system, which is involved in reward, motivation, and mood.

Pramipexole's activity at D3 receptors may explain its potential benefits on non-motor symptoms such as depression and apathy, but also its association with impulse control disorders.

Unlike ergot-derived dopamine agonists (such as bromocriptine and cabergoline), pramipexole has a non-ergot chemical structure and is therefore not associated with the fibrotic complications (cardiac valvulopathy, retroperitoneal fibrosis, pulmonary fibrosis) that led to restrictions on ergot dopamine agonist use.

Non-ergot dopamine agonists are now the preferred class within this drug group.

For restless legs syndrome, pramipexole is thought to act on dopaminergic pathways in the spinal cord and subcortical brain regions that modulate sensorimotor integration.

The precise mechanism by which dopamine agonists relieve RLS symptoms is not fully established, but clinical trials have consistently demonstrated their efficacy.

Clinical evidence and UK prescribing guidance

NICE guideline NG71 (Parkinson's disease in adults, 2017) recommends offering a choice of levodopa, dopamine agonist, or monoamine oxidase B (MAO-B) inhibitor as initial therapy for motor symptoms of Parkinson's disease.

The choice should take into account the patient's individual clinical circumstances, lifestyle, preferences, and the potential benefits and risks of each class.

Dopamine agonists may be preferred in younger patients (under 60 or with a life expectancy of more than 10 years) to delay levodopa-related motor complications (wearing off, dyskinesia), although NICE acknowledges that levodopa is the most effective symptomatic treatment and should not be withheld when it is needed.

Pramipexole has been evaluated in large randomised controlled trials for both Parkinson's disease and restless legs syndrome.

In Parkinson's disease, trials have demonstrated significant improvements in motor function scores compared with placebo.

The CALM-PD trial compared initial treatment with pramipexole versus levodopa and showed that pramipexole delayed the onset of dyskinesia, although levodopa provided greater motor improvement.

In restless legs syndrome, the RLS-1 and RLS-2 trials demonstrated that pramipexole significantly reduced symptom severity compared with placebo.

The BNF notes that all patients starting a dopamine agonist should be informed about the risk of excessive daytime sleepiness, sudden-onset sleep, and impulse control disorders. Monitoring for these side effects should be ongoing throughout treatment.

Pramipexole compared with other Parkinson's treatments

Several dopamine agonists are available in the UK: pramipexole, ropinirole, and rotigotine (transdermal patch). All three are non-ergot dopamine agonists with similar efficacy and side-effect profiles.

Ropinirole is available as both immediate-release and prolonged-release tablets.

Rotigotine is applied as a once-daily transdermal patch, which may suit patients who have difficulty swallowing or who prefer a non-oral route.

The choice between dopamine agonists is guided by individual tolerability, convenience, and prescriber experience.

Levodopa (usually combined with a decarboxylase inhibitor as co-beneldopa or co-careldopa) remains the gold standard for symptom control in Parkinson's disease.

MAO-B inhibitors (selegiline, rasagiline, safinamide) and catechol-O-methyltransferase (COMT) inhibitors (entacapone, opicapone) are used to extend the effect of levodopa or as adjunctive therapy.

Amantadine may be used for dyskinesia. The management of Parkinson's disease is complex and should be guided by a specialist neurologist or geriatrician with expertise in movement disorders.

Dosage and administration

For Parkinson's disease with immediate-release pramipexole, the starting dose is 88 microgram base three times daily.

The dose is increased at weekly intervals following the recommended titration schedule up to a maximum of 1.05 mg base three times daily (3.15 mg total daily dose).

Each increase should be guided by clinical response and tolerability. Immediate-release tablets can be taken with or without food; taking them with food may reduce nausea.

For Parkinson's disease with prolonged-release pramipexole, the starting dose is 260 microgram base once daily, increased at weekly intervals to the minimum effective dose up to a maximum of 3.15 mg base once daily.

Prolonged-release tablets must be swallowed whole. Patients stabilised on immediate-release tablets may be switched to prolonged-release tablets at the same total daily dose.

For restless legs syndrome, pramipexole immediate-release tablets are used at a starting dose of 88 microgram base once daily, taken 2 to 3 hours before bedtime.

The dose may be doubled at intervals of 4 to 7 days to a maximum of 540 microgram base daily.

The lowest effective dose should be used for the shortest necessary duration due to the risk of augmentation.

Dose adjustment is essential in renal impairment. Check with the BNF or your prescriber for appropriate dosing if your kidney function is reduced.

Side effects of pramipexole

Common side effects

Nausea, dizziness, drowsiness, insomnia, constipation, headache, and fatigue are the most frequently reported side effects.

Nausea is most prominent during the dose-titration phase and usually improves with continued use. Taking pramipexole with food may help.

Orthostatic hypotension (dizziness on standing) may occur, particularly during dose increases.

Excessive sleepiness and sleep attacks

Dopamine agonists, including pramipexole, can cause excessive daytime sleepiness and sudden-onset sleep episodes. These can occur without preceding drowsiness and without warning.

Patients must be informed of this risk before starting treatment. If sudden-onset sleep occurs, the patient must stop driving, inform the DVLA, and consult their prescriber.

The dose may need to be reduced or the drug discontinued.

Impulse control disorders

Pathological gambling, compulsive spending, binge eating, hypersexuality, and other compulsive behaviours have been reported in patients taking dopamine agonists.

These behaviours can be devastating to the patient and their family. NICE NG71 recommends discussing the risk before starting treatment and monitoring throughout.

Patients and carers should be encouraged to report any unusual behaviours.

If an ICD develops, the dopamine agonist dose should be reduced or the drug discontinued under specialist guidance.

Psychiatric effects

Hallucinations (usually visual, such as seeing people or animals that are not there), confusion, paranoia, and delusions are more common in elderly patients and at higher doses.

If significant psychiatric symptoms develop, the dose should be reduced or the drug stopped, with specialist input.

Augmentation in restless legs syndrome

Augmentation is a treatment-related worsening of RLS symptoms, in which symptoms start earlier in the day, become more intense, or spread to other body parts (for example, the arms).

It is the main limitation of long-term dopamine agonist use in RLS. If augmentation occurs, do not increase the dose.

Contact your prescriber for advice on gradual withdrawal and alternative treatment options.

When to seek medical advice

Contact your prescriber or specialist nurse if you experience hallucinations, confusion, sudden-onset sleep, signs of impulse control disorder, or worsening of RLS symptoms (augmentation).

Seek urgent medical attention if you develop high fever with muscle rigidity and altered consciousness (possible neuroleptic malignant-like syndrome after abrupt withdrawal). Call 999 in an emergency.

Report suspected adverse reactions to the MHRA at yellowcard.mhra.gov.uk .

Warnings and precautions

Do not stop abruptly

Pramipexole must never be stopped suddenly.

Abrupt discontinuation can cause dopamine agonist withdrawal syndrome (DAWS), with symptoms including anxiety, panic attacks, depression, irritability, sweating, nausea, generalised pain, and drug cravings.

In severe cases, neuroleptic malignant-like syndrome (high fever, severe rigidity, altered consciousness) can occur. Always reduce the dose gradually under medical supervision.

Impulse control disorders

All patients starting pramipexole must be informed about the risk of developing impulse control disorders.

Both the patient and their partner, carer, or family member should be involved in this discussion. Monitoring should be ongoing throughout treatment, not just at initiation.

Driving and sleep

The DVLA requires patients taking dopamine agonists to notify them if sudden-onset sleep or excessive daytime sleepiness occurs. Driving must cease until episodes have been controlled. Patients should also avoid operating dangerous machinery if affected.

Renal impairment

Pramipexole is eliminated primarily by the kidneys. Dose reduction is required if creatinine clearance falls below 50 mL/min. Renal function should be monitored, particularly in elderly patients.

Pregnancy and breastfeeding

Limited human data are available. Pramipexole should be used during pregnancy only if clearly necessary. It inhibits prolactin secretion and may suppress lactation; it is not recommended during breastfeeding.

Drug interactions

Antipsychotics (dopamine antagonists such as haloperidol, risperidone, olanzapine) may reduce the effectiveness of pramipexole and should generally be avoided in Parkinson's disease.

Metoclopramide and prochlorperazine (dopamine antagonists) should be avoided as antiemetics; use domperidone instead. Cimetidine and amantadine may increase pramipexole levels. Sedating medicines (benzodiazepines, opioids, alcohol) may enhance drowsiness.

Living with Parkinson's disease

Parkinson's disease management extends beyond medication.

Regular exercise, including walking, cycling, dancing, tai chi, and strength training, has been shown to improve mobility, balance, mood, and quality of life.

Physiotherapy, occupational therapy, and speech and language therapy play important roles at various stages of the condition.

Psychological support, including access to clinical psychology and peer support groups, can help with the emotional impact of living with a chronic progressive condition.

Parkinson's UK provides information, support, and advocacy for people living with Parkinson's disease and their families in the United Kingdom.

How to get pramipexole in the UK

Pramipexole is available on NHS prescription from your GP, neurologist, or Parkinson's disease specialist team. Generic pramipexole tablets (both immediate-release and prolonged-release) are widely available and cost-effective.

The standard NHS prescription charge in England is 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Sources

• Pramipexole Tablets, Summary of Product Characteristics (EMC)
• Pramipexole, British National Formulary (BNF)
• NICE NG71: Parkinson's disease in adults
• Parkinson's disease, NHS
• Restless legs syndrome, NHS
• Parkinson's UK
• MHRA Yellow Card Scheme